The stomach is a complex environment and direct drug delivery tends to reduce the efficiency of drug treatment for H. pylori and also affects other bacteria in the stomach. Targeted development of drug delivery systems with high affinity to H. pylori can increase the drug concentration around H. pylori to achieve better therapeutic effects. Ace Therapeutics assists in the development of drug delivery systems for the treatment of H. pylori and provides to develop four types of H. pylori targeted drug delivery systems (TDDS) based on the properties of H. pylori.
Fig. 1 Development of drug delivery systems based on the properties of H. pylori.
Development of H. pylori TDDS based on the pH homeostasis mechanism of H. pylori
H. pylori maintains pH homeostasis by decomposing urea. We take advantage of the properties of Urel to transport urea and provide to develop ureido-conjugated delivery systems to achieve ureido-directed transport that targets Urel. Specially, we provide to develop ureido-conjugated pH-sensitive delivery systems. It enables the release of drugs (such as antibiotics) around H. pylori and in a neutral environment that is based on urea decomposition. Overall, this drug delivery system enables the release of drugs at the optimal time and at the optimal location.
Development of H. pylori TDDS based on the adhesion properties of H. pylori
H. pylori relies on various adhesins to adhere to gastric cells. We exploit the natural adhesion properties of H. pylori and offer to add gastric cell membrane coating and H. pylori affinity membrane molecules for drug delivery systems. For general H. pylori TDDS, we offer gastric cell culture, membrane derivation, and membrane coating services. For H. pylori TDDS with special adhesion needs, we offer to add specific membrane coatings, such as sialic acid, cell adhesion molecule (CEACAM -1, -3, -5, and -6), blood group antigens (Leb, A-Leb, and B-Leb), integrin (α5β1, αVβ3, αVβ5, and αVβ6), and sialylated glycan (s-Lex and Lex) coatings. In particular, we also offer to add the coating of the [VITA]-[VITA]-x-x-D-[DN] sequence of E-cadherin. This delivery system can protect the gastric cell layer from damage while delivering the drug to H. pylori.
Development of H. pylori TDDS based on the outer membrane proteins of H. pylori
Many outer membrane proteins (OMPs) of H. pylori have corresponding signal peptides. We deeply analyze the characteristics of these signal peptides and provide services for the development of H. pylori TDDS that are coated with peptides that mimic the signal peptides of H. pylori OMPs. During the development process, we will be careful to remove the virulent part of OMPs.
Development of H. pylori TDDS based on the antimicrobial peptides
Antimicrobial peptides have a good affinity for the cell membrane of bacteria, and we take advantage of this property to provide H. pylori TDDS development with antimicrobial peptide coatings. This drug delivery system can better enable the combined therapy of antimicrobial peptides and antibiotics.
Contact us
Ace Therapeutics offers a wide range of development services for H. pylori TDDS. We take adequate consideration of the properties of H. pylori, and we offer to develop drug delivery systems that take advantage of these properties. If you have needs in this area, please contact us to discuss your needs.
References
- Bonsor, D. A.; Sundberg, E. J. Roles of adhesion to epithelial cells in gastric colonization by Helicobacter pylori. Helicobacter pylori in Human Diseases. 2019: 57-75.
- Neshani, A.; et al. Review of antimicrobial peptides with anti-Helicobacter pylori activity. Helicobacter. 2019, 24(1): e12555.
※ All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
